Cold agglutinin disease is a rare autoimmune hemolytic anemia characterized by hemolysis that is caused by activation of the classic complement pathway. Sutimlimab, a humanized monoclonal antibody, ...
Sanofi’s Enjaymo, the only approved drug therapy for a rare and debilitating blood disorder, is being acquired by Recordati in a deal that helps the Italian company build its rare disease portfolio ...
Cold agglutinin disease (CAD) is a rare subtype of autoimmune haemolytic anaemia (AIHA) where autoantibodies, predominantly of the IgM class, bind to red blood cells at reduced temperatures. This ...
Results from CADENCE, the first and largest multinational prospective registry for patients with CAD/CAS, describe safety events observed in patients treated with sutimlimab, with an average treatment ...
Recordati SpA is shelling out $825 million up front for global rights to Enjaymo (sutimlimab), the only therapy approved for treating the rare disease cold agglutinin disease. In the deal with Sanofi ...
The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...
The U.S. FDA has approved Sanofi SA’s treatment for cold agglutinin disease (CAD), sutimlimab, after the drug was initially rejected by the regulator for technical reasons in 2020. Paris-based ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results